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Fever in critically ill patients may have various etiologies. It usually triggers a multimodal diagnostic workup.1 Infectious disease should primarily be ruled out to pre-
clude possible evolution to sepsis, multiple organ dysfunction, 
and eventual death.2 However, any empirical antibiotic therapy 
and other interventions triggered by hyperthermia may poten-
tially be harmful, if unjustified.1 This is particularly true when 
an elevated body temperature is actually drug-induced.3,4
Dexmedetomidine is a highly selective α2-adrenergic 
agonist used to perform mild to moderate sedation in criti-
cally ill patients.5 Febrile episodes have been attributed to 
dexmedetomidine administration in several case reports.6–11 
Here, we present 9 patients in a cardiovascular intensive care 
unit (ICU) with the onset of hyperthermia >38.5°C during 
dexmedetomidine administration. Our goal is to increase 
awareness and stimulate further research on this topic.
METHODS
Data collection from the electronic patient information 
system was approved by the Institutional Review Board 
(Kantonale Ethikkommission Zurich, BASEC-ID: PB_2016-
00333) and the need for informed consent waived. Statistics 
are descriptive, and results are given as median (inter-
quartile range) or numbers (percentage). Of 1918 patients, 
admitted to our ICU during 2013 and 2014 after cardiac or 
major vascular surgery, 200 (10.4%) patients were treated 
with dexmedetomidine. Nine (4.5%) of these patients were 
selected for this case series (convenience sample) because of 
the occurrence of hyperthermia >38.5°C during dexmedeto-
midine administration.
In our ICU, dexmedetomidine is used for long-term 
sedation, during weaning from mechanical ventilation, 
and for the treatment of hyperactive delirium. It is usu-
ally started at a dose of 0.7–1.0 μg/kg/h and titrated up to 
1.4 μg/kg/h, according to clinical needs.5 Dexmedetomidine 
is discontinued if (1) continuous sedation can be omitted or 
delirium has improved, (2) hemodynamic instability occurs 
(norepinephrine >0.3 μg/kg/min, atrioventricular block ≥II°, 
or bradycardia <55 bpm in the absence of a pacemaker), or (3) 
drug fever is suspected. In our ICU, microbiological sampling 
is usually triggered by a rise of the body temperature >38.5°C. 
An empirical antibiotic therapy is subsequently started if an 
infection is suspected or if organ functions deteriorate.
All patients were screened for potential infectious and non-
infectious causes of hyperthermia.1 The association between 
dexmedetomidine and hyperthermia was assessed by 2 differ-
ent ADR algorithms: The World Health Organization-Uppsala 
Monitoring Centre (WHO-UMC) Causality Assessment 
and the Naranjo ADR scale. A causality assessment by the 
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WHO-UMC criteria is accomplished by comparison of the 
drug-effect relationship in question with a table of predefined 
statements and yields the following categorization: unclas-
sifiable, unclassified, unlikely, possible, probable, and cer-
tain (http://www.whoumc.org/Graphics/26649.pdf). The 
Naranjo ADR scale is a questionnaire-based scoring system 
(0 to ≥9 points), grading a drug-effect relationship into the 
following categories: doubtful (0), possible (1–4), probable 
(5–8), and definite (≥9).12 Two ADR assessment methods were 
applied because the level of causality has been reported to dif-
fer between different pharmacovigilance algorithms.13,14
RESULTS
Nine patients (age 67 [64–72] years, 5 [56%] male) under con-
sideration underwent cardiac surgery (n = 8) or major vas-
cular surgery (n = 1). Cardiac surgery was performed with 
cardiopulmonary bypass in 7 (78%) patients. Table  1 indi-
cates the patients’ characteristics, details of dexmedetomi-
dine administration, and the occurrence of hyperthermia. 
Dexmedetomidine was initiated on postoperative day 1 (1–4) 
for the treatment of delirium in 2 patients (patients 4 and 
6) and for sedation in 7 patients. The commencement dose 
was 1.0 (0.6–1.0) μg/kg/h. Hyperthermia was detected after 
6 (4–10) hours at a dexmedetomidine dose of 1.0 (0.8–1.3) 
μg/kg/h. The maximum body temperature of 39.0°C (38.8–
39.2°C) was observed after 11 (6–29) hours at a dexmedeto-
midine dose of 1.0 (0.8–1.0) μg/kg/h. Hyperthermia was 
present during 34 (12–38) hours, while dexmedetomidine 
was administered during 26 (9–35) hours. In no patient did 
the administration of acetaminophen and/or metamizole 
or the insertion of an intravenous cooling device (patient 1) 
lower the body temperature <38.5°C. After dexmedetomidine 
discontinuation, the body temperature declined ≤38.5°C and 
≤38.0°C after 3 (1–8) and 4 (3–9) hours, respectively. The tem-
poral relationship between dexmedetomidine administration 
and hyperthermia is depicted in the Figure. Dexmedetomidine 
was discontinued because of (a) assumed drug fever (patients 
1, 8, and 9), (b) discontinuation of sedation (patients 2, 3, 4, 
and 5), (c) insufficient sedative effect (patient 7), and (d) occur-
rence of a convulsive status epilepticus (patient 6).
Two patients (patients 3 and 4) received dexmedetomi-
dine twice. In patient 3, hyperthermia occurred only during 
the second administration, with a 2-day interval in-between. 
In contrast, in patient 4, hyperthermia occurred only during 
the first administration, with a 6-day interval in-between.
As far as infectious diseases were concerned, 4 of 9 (44%) 
patients were under antibiotic therapy for endocarditis and/
or pacemaker infection (patients 2, 4, and 6) and for pneumo-
nia (patient 3). After the onset of hyperthermia, the antibiotic 
therapy was empirically changed or initiated in 4 of 9 (44%) 
patients (patients 1, 2, 4, and 7). Retrospectively, no unam-
biguous focus of infection was identified in any patient, and 
microbiological sampling results were negative for relevant 
pathogens. Table 1 presents the details of infection manage-
ment and microbiological investigations for all patients.
Noninfectious causes present during hyperthermia 
are given in Table  2. One patient (patient 6) experienced 
a convulsive status epilepticus and 1 patient (patient 2) 
had a thrombosis in a jugular vein. In all patients, labora-
tory inflammation markers were elevated. As far as drug 
exposure was concerned, a temporal association with 
hyperthermia was found exclusively for dexmedetomidine 
in all patients. The likelihood of an ADR was categorized by 
the WHO-UMC criteria as “probable” in all patients and by 
the Naranjo ADR scale as “probable” in 1 patient (patient 3) 
and “possible” in 8 patients (Table 1).
Individual case descriptions, a table summarizing all 
drugs given prior to or during dexmedetomidine expo-
sure, and the Naranjo questionnaire scores are provided in 
Supplemental Digital Content 1–3, Material 1, http://links.
lww.com/AA/B942, Table 1, http://links.lww.com/AA/
B943, and Table 2, http://links.lww.com/AA/B944.
DISCUSSION
In this case series, we present 9 (4.5%) patients with clini-
cally relevant hyperthermia of 200 patients with exposure 
to dexmedetomidine during a 2-year period in our ICU. 
The observed drug-effect relationship is highly suggestive 
of drug fever.3 Because our 9 patients represent a conve-
nience sample, the true incidence of dexmedetomidine-
associated hyperthermia in our ICU cannot be determined 
with certainty. However, in 2 multicenter, randomized 
trials involving ventilated ICU patients, pyrexia has been 
reported as an adverse drug event in the dexmedetomi-
dine group in 16 of 247 (6.5%) patients (MIDEX trial) and 
in 13 of 246 (5.3%) patients (PRODEX trial).15 The Swiss 
Drug Compendium reports an incidence of between 1% 
and 10% of treated patients, without providing further 
details or references (https://compendium.ch/mpro/
mnr/23800/html/de).
Our results are supported by several case reports that 
describe a similar pattern of hyperthermia during dexme-
detomidine administration: onset of hyperthermia after 
dexmedetomidine initiation (range 3–24 hours), persistence 
of hyperthermia during dexmedetomidine administration 
(body temperature >38°C up to 7 days), and resolution of 
hyperthermia after dexmedetomidine discontinuation (range 
2–12 hours).6–11 A summary of these case reports is presented 
in Table 3.
Drug fever is frequently considered a diagnosis of exclu-
sion. Confounding factors are common particularly in critically 
ill patients, in which multiple pathologies and multiple drug 
treatments are usually present at the same time. Therefore, all 
infectious and noninfectious causes of hyperthermia must be 
excluded by a multimodal diagnostic workup.1,3
In this case series, all patients admitted with an infection 
were under adequate antibiotic therapy. Retrospectively, no 
patient had a new focus of infection and/or a positive micro-
biological sampling result, rendering infections unlikely 
for the febrile episodes. However, the onset of hyperther-
mia triggered costly microbiological investigations in 8 of 
9 (89%) patients and the initiation of an empirical antibiotic 
therapy in 4 (44%) of 9 patients, which might retrospectively 
be considered inappropriate.
In 3 published case reports, infections were confounding 
factors of fever during dexmedetomidine administration: 
Harding et al6 reported a patient with methicillin-resistant 
Staphylococcus aureus pneumonia and concurrent bactere-
mia, Faust and Sutton9 described a patient with hyperther-
mia during an acute exacerbation of chronic obstructive 
lung disease, and Lowenstein et al10 reported a patient after 
multiple organ transplantation with respiratory failure 
Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
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A B
Figure. A and B, The body temperature (BT) of 9 
patients over time in relation to dexmedetomidine 
(DEX) administration. Values are given as median 
(interquartile range). A, The time points indicate 
(1) 4 hours prior to DEX administration, (2) start 
of DEX administration, (3) first BT >38.5°C. B, The 
time points indicate (1) end of DEX administra-
tion, (2) resolution of hyperthermia ≤38.5°C, and 
(3) BT ≤38.0°C.
Table 2. Noninfectious Etiologies of Hyperthermia, Differential Diagnoses of All Case Series Patients and 
Likelihood of a Relationship With Observed Hyperthermia
Noninfectious Etiology of Hyperthermia
Differential Diagnosis of Case  
Series Patients With Potential for 
Hyperthermia
Relationship of Differential  
Diagnosis With Observed  
Hyperthermia Period
Central temperature dysregulation # 2 and 6: status epilepticus Possible for # 6
 # 3: out of hospital cardiac arrest  
Drugs All patients Possible: presence of a temporal relationship only 
for DEX
Endocrine disorders No patient …
Heat stroke No patient …
Immunological and inflammatory  
diseases
# 2: history of ANA-positive rheumatoid  
disease
Unlikely: clinically no active lesion, hydrocortisone 
administration postoperative
Malignancy # 9: history of metastasized neuroendocrine 
tumor in pancreas
Unlikely
Metabolic disorders # 1 and 4: history of gout Unlikely: absence of a clinically active lesion
Reactions to blood products All patients, except for # 8 Unlikely: absence of a temporal relationship
Inflammation after tissue destruction All patients: after major surgery Possible: inflammatory blood markers above normal 
range
Thromboembolic disease # 2: thrombus in a jugular vein Possible
Adapted from Rehman and deBoisblanc1 and Walter et al.4
Abbreviations: #,  patient number; ANA,  antinuclear autoantibodies; DEX, dexmedetomidine.
following aspiration. In all these patients, great efforts and 
resources were spent to exclude infections, reflecting the 
difficulties in daily praxis to correctly diagnose drug fever 
in time.
The screening of our patients for noninfectious causes 
of fever revealed 3 common factors. First, 8 of 9 patients 
had received blood products, but transfusion reactions 
were considered unlikely in the absence of a temporal 
relationship with hyperthermia. Second, all patients had 
laboratory signs of an inflammatory response to major 
surgery. Third, all patients had received several drugs in 
common (Supplemental Digital Content 2, Table 1, http://
links.lww.com/AA/B943), but a temporal relationship 
with hyperthermia was only found for dexmedetomidine.
This drug-effect relationship was assessed by 2 ADR 
causality assessment methods.13 The WHO-UMC algorithm 
favored a higher ratio of “probable” ADR cases (100%) than 
the Naranjo ADR scale (11%). Differences in the level of 
causality between ADR algorithms have been described,13,14 
and the incongruence of our results is explained by meth-
odological differences. Infectious and noninfectious causes 
for hyperthermia were considered possible, but unlikely, 
in our patients. According to the WHO-UMC criteria, this 
was best reflected by the category “probable.” As for the 
Naranjo ADR scale, the deduction of 1 point for possible 
alternatives of hyperthermia placed all patients but one in 
the category “possible.” It was the drug-effect reaction pat-
tern that placed patient 3 in the category “probable.”
The Naranjo assessment was used in 2 of the published 
case reports: the association between dexmedetomidine and 
hyperthermia was categorized “possible” in a patient fol-
lowing cardiac surgery8 and “probable” in a patient with 
exacerbated chronic obstructive lung disease.9 A “definite” 
or “certain” drug-effect relationship, the highest ADR 
Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
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grading category, between dexmedetomidine and hyper-
thermia has not been described yet.
Febrile disorders during dexmedetomidine administration 
have been reported as ADRs to the WHO global pharmaco-
vigilance database (http://www.vigiaccess.org). However, 
adverse events reported to these databases usually lack detailed 
case information, and the assessment of the causal relationship 
to the drug is often not possible. Drugs may cause fever by 
several mechanisms: (1) drug effects on thermoregulation, (2) 
drug administration-related reactions, (3) pharmacologic drug 
actions, (4) idiosyncratic responses, and (5) hypersensitivity/
immunologic reactions, which are the most common.3 However, 
the results of this case series and the published case reports are 
not entirely explained by one common mechanism. The drug-
effect reaction pattern of patient 3 with the occurrence of hyper-
thermia exclusively during the rechallenge of dexmedetomidine 
might point to an immunologic/allergic mechanism, which 
was also considered possible in the case report of Okabe et al.11 
However, dexmedetomidine did not trigger a uniform reac-
tion during the rechallenge in patient 4 of this case series. 
Furthermore, to the best of our knowledge, hyperthermia 
occurred during the first exposure to dexmedetomidine in 
the other case series patients, which in summary questions an 
underlying immunologic mechanism. Alternatively, an influ-
ence on thermoregulation by α2-agonists has been proposed 
in 1 published case report.7 However, in this case series, no 
dose-dependent effect of dexmedetomidine on the occurrence 
of hyperthermia was found, as assumed by Harding et al6 and 
Faust and Sutton.9 Of interest, a preclinical study in rodents 
investigated antipyretic properties of α2-agonists, including 
dexmedetomidine, and demonstrated an inhibition of brown 
adipose tissue and shivering thermogenesis.16 This cannot per 
se be used as an argument against dexmedetomidine-induced 
hyperthermia, but instead underlines the need for further 
research to investigate the corresponding mechanism.
In summary, we described 9 critically ill patients with 
the onset of clinically relevant hyperthermia during dexme-
detomidine administration, highly suggestive of drug fever. 
As risk factors and underlying mechanisms are uncertain to 
date, further research on this topic is warranted. E
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